Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDTRONIC PLC

(MDT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medtronic plc Launches New Generation Drug Coated Balloon Catheter in Europe for Treatment of Coronary Artery Disease

07/26/2021 | 05:00am EDT

Medtronic plc announced the launch of the Prevail™ drug coated balloon (DCB) Catheter in Europe following CE (Conformité Européene) mark. The newest coronary DCB on the market, the Prevail DCB is used during percutaneous coronary intervention (PCI) procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease (CAD). During the catheter-based procedure, the balloon inflates within the artery, while the drug is delivered to the arterial tissue where it is absorbed. The Prevail DCB utilizes a rapid absorption drug – paclitaxel – to enable treatment of de novo lesions, small vessel disease, and in-stent restenosis (ISR). DCB angioplasty does not require a permanent implant and is often used in cases where the implantation of a drug-eluting stent (DES) is not desirable or is technically challenging. The Prevail DCB builds on the excellent safety and efficacy demonstrated in the previous generation IN.PACT™ Falcon DCB clinical program and was reaffirmed by the PREVAIL Study presented at the 2020 PCR e-Course conference. In the PREVAIL Study, the Prevail DCB showed exceptional performance in patients with complex lesions, including those with small vessels and those treated for in-stent restenosis, which occurs when a portion of a stented artery is blocked. The Prevail DCB showed favorable late loss (0.05 ± 0.44 mm) at 6 months and a strong safety profile that included no stent thrombosis, target vessel myocardial infarction (TVMI), or cardiac death and low clinically driven target lesion revascularization (6%) out to one year for all patients. The Prevail DCB uses PowerTrac™, the same enhanced technology used in the delivery system for the Medtronic Resolute Onyx™ DES, to provide superior deliverability and two times more pushability than the previous IN.PACT Falcon technology enabling greater control for tortuous anatomies. In addition, Prevail DCB has a low crossing profile for exceptional crossability. The Prevail DCB is the latest addition to the Medtronic coronary portfolio, which also includes the market-leading Resolute Onyx DES in sizes ranging from 2.0-5.0 mm, the Euphora™ semicompliant balloon dilatation catheter, the DxTerity™ Diagnostic Angiography Catheter line, and the Telescope™ Guide Extension Catheter. The Prevail DCB is available for use in Europe and is not approved in the U.S. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.


ę S&P Capital IQ 2021
All news about MEDTRONIC PLC
09/27MEDTRONIC : Says First Procedure Using Its Robotic-Assisted Surgery System Performed in In..
MT
09/27MEDTRONIC : First Procedure in Asia-Pacific Performed with Medtronic Hugo™ Robotic-A..
AQ
09/24IAC/INTERACTIVECORP : IAC in Talks to Acquire Meredith in Potential $2.5 Billion Deal
MT
09/23AXONICS : Confident It Doesn't Infringe Any Medtronic Patent Despite US Patent Office Pane..
MT
09/23MEDTRONIC : Wins US Patent Office's Affirmation On Three Bladder Device Patents
MT
09/23MEDTRONIC PLC : Ex-dividend day for
FA
09/22MEDTRONIC : Enrolls First Patient in Pediatric Trial for Treatment of Scoliosis
MT
09/22MEDTRONIC : U.S. Patent Office Completes Review of Medtronic Patents, Rejects More Axonics..
PR
09/22MEDTRONIC : Begins Pediatric Clinical Trial of Spinal Tether for Treatment of Scoliosis
AQ
09/22Medtronic plc Begins Pediatric Clinical Trial of Spinal Tether for Treatment of Scolios..
CI
More news
Analyst Recommendations on MEDTRONIC PLC
More recommendations
Financials (USD)
Sales 2022 32 991 M - -
Net income 2022 5 704 M - -
Net Debt 2022 20 694 M - -
P/E ratio 2022 32,4x
Yield 2022 1,87%
Capitalization 173 B 173 B -
EV / Sales 2022 5,88x
EV / Sales 2023 5,52x
Nbr of Employees 90 000
Free-Float 99,7%
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MDT | IE00BTN1Y115 | MarketScreener
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 28
Last Close Price 128,75 $
Average target price 145,92 $
Spread / Average Target 13,3%
EPS Revisions
Managers and Directors
Geoffrey Straub Martha Chairman & Chief Executive Officer
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Laura Mauri Chief Clinical & Regulatory Officer, Senior VP
Richard E. Kuntz Chief Medical & Scientific Officer, Senior VP
Gregory L. Smith Executive VP-Global Operations & Supply Chain
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC9.91%173 273
ABBOTT LABORATORIES10.13%220 485
BECTON, DICKINSON AND COMPANY0.48%72 711
HOYA CORPORATION29.36%62 143
ALIGN TECHNOLOGY, INC.31.19%57 302
SARTORIUS STEDIM BIOTECH77.82%55 891